George's journal

Quote




























Anonymous said:
You know what beats getting a three? Giving Cristian a one
Click to expand...

He deserves it for speaking the truth. What gives with Phase 3 #10. Can we ever make enough money to justify all these phase 3 studies? Reception in Denver is so lukewarm and the KOLs said we should be doing HTH against Humira the gold standard. Someone shoot us. I"m tire of the Rat looking at her with googly eyes. Just plain fukkin gross. Wish he'd be happy with his fat Greek wife.
 




Anonymous said:
He deserves it for speaking the truth. What gives with Phase 3 #10. Can we ever make enough money to justify all these phase 3 studies? Reception in Denver is so lukewarm and the KOLs said we should be doing HTH against Humira the gold standard. Someone shoot us. I"m tire of the Rat looking at her with googly eyes. Just plain fukkin gross. Wish he'd be happy with his fat Greek wife.
Click to expand...

We need more studies because we did the wrong ones first. Didn't you hear the FDA feedback?
 




















Re: Writing my CV for TMS

Executive PubMed said:
Ok not a great scientific output, but a lot of Charisma

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).
Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R.
Ann Rheum Dis. 2010 Mar;69(3):510-6. doi: 10.1136/ard.2009.119016. Epub 2009 Nov 23. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.
Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, Jorch G, Nadler SG, Bröker B, Hebel K, Brunner-Weinzierl MC.
J Immunol. 2009 May 1;182(9):5342-51. doi: 10.4049/jimmunol.0801624.

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.
Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P.
Ann Rheum Dis. 2009 Jul;68(7):1220-7. doi: 10.1136/ard.2008.091876. Epub 2008 Sep 4. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.
Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM.
Ann Rheum Dis. 2008 Aug;67(8):1084-9. Epub 2007 Dec 17.


Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.
Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL.
Arthritis Rheum. 2007 Aug;56(8):2557-65.


Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects.
Tay L, Leon F, Vratsanos G, Raymond R, Corbo M.
Arthritis Res Ther. 2007;9(2):R38.

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW.
J Rheumatol. 2006 Nov;33(11):2162-6. Epub 2006 Oct 1.


CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus.
Vratsanos GS, Jung S, Park YM, Craft J.
J Exp Med. 2001 Feb 5;193(3):329-37.
Click to expand...

We need a Christian not a Rat to lead us through an ad comm. at least he knew the drug and program. Why can't we keep the good ones?
 




























Top Bottom
Back
Quote